People who have an inflammatory bowel disease like ulcerative colitis often have problems caused by inflammation in other parts of their bodies. One of these is a skin condition called pyoderma ...

Pyoderma gangrenosum was first described as an extraintestinal manifestation of inflammatory bowel disease (IBD) by Brunsting and colleagues in 1930. 1 They described painful enlarging necrotic ulcers ...

Leg ulcers form when skin on your leg breaks open. These breaks or sores let air and bacteria travel into your skin’s tissue. For most people, leg ulcers will heal on their own and won’t need medical ...

A systematic review of 63 cases found that pyoderma gangrenosum (PG) during pregnancy or postpartum was often misdiagnosed, delaying treatment and leading to inappropriate interventions. Researchers ...

To the Editor: Weenig et al. (Oct. 31 issue) 1 stress the need for extensive investigations in cases of skin ulcers that are suggestive of pyoderma gangrenosum. However, their recommendation of ...

In a recently published systematic review, researchers determined that VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome typically presents in men, with atypical morphology and ...

Dear Dr. Roach: I am a 74-year-old woman who is in good health. I was diagnosed with pyoderma gangrenosum on my left leg and I was in a lot of pain. Can you tell me the cause of this rare disease?

With the initial presentation of nodules, a clinician must rule out infectious disorders including various bacterial, viral, and parasitic infections. Other vasoocclusive disorders such as multiple ...

Please provide your email address to receive an email when new articles are posted on . A minimal important difference of 7-day pain scores was a 2-point improvement on an 11-point scale. A 2-point ...

A differential diagnosis is a list of possible conditions that share the same symptoms. For example, fatigue can be a symptom of anemia, depression, heart disease, thyroid disease, and many other ...

Vilobelimab is a first-in-class anti-human complement factor C5a monoclonal antibody. The Food and Drug Administration (FDA) has granted Fast Track designation to vilobelimab for the treatment of ...